Reverse transcriptase-polymerase chain reaction (RT-PCR) has been the major technology used to assess mRNA splicing in a variety of cancer susceptibility genes, including BARD1. However, incorrect positioning of PCR primers can result in key splicing events not being detected and lead to a misinterpretation of splicing events. Here, BARD1 is linked to cancer.